FDA authorizes glucose and ketone monitoring in one wearable
Signals InboxAugust 26, 2026MedTech
Regulation just turned a technical possibility into a commercial one. Ketones finally join continuous glucose.
BREAKING NEWS! Especially for diabetes patients!
— Berci Meskó, MD, PhD (@Berci) August 26, 2026
The US FDA just authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people aged 2 years and older living with diabetes.
That is the first wearable device in the world to continuously monitor both… pic.twitter.com/NQd14Mmjwx
Q1What did the FDA authorize?
According to the official source, the FDA authorized Abbott's Libre Duo 10 Day system for people aged two and older with diabetes. It is the first U.S. wearable to continuously monitor ketones and the first device globally to continuously monitor glucose and ketones together.
Q2Why add ketones to glucose?
Rising ketones can warn that the body lacks enough insulin and is moving toward diabetic ketoacidosis. Continuous measurement can surface that risk earlier than waiting for symptoms or a manual ketone test.
Q3Who benefits most?
People using insulin, especially those at higher risk of DKA, gain a second real-time safety signal. The value is strongest when glucose and ketone trends are interpreted together rather than as separate snapshots.
Q4What changes in diabetes wearables?
CGMs are expanding from glucose tracking into broader metabolic monitoring. That creates room for sensors that combine multiple biomarkers and for software that turns those streams into earlier warnings.